Targeting the Inhibition of B-Cell Lymphoma 2 Protein for the Treatment of Cancer.

The invention in this patent application relates to 1,3,4,7-tetrahydro-2 H -pyrrolo[3',2':5,6]pyrido[2,3- b ][1,4]oxazepine derivatives represented generally by Formula 1. These compounds are Bcl-2 inhibitors and may be useful for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and/or acute lymphocytic lymphoma.